Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01537029 · ClinicalTrials.gov registry record · Phase 4

Effect of Weight on the Population Pharmacokinetic Analysis of Doxorubicin and Cyclophosphamide

A Phase 4 study, sponsored by Texas Tech University Health Sciences Center.

Completed
Registry status
Phase 4
Development phase
15
Enrollment target

NCT01537029: Completed Phase 4 study, sponsored by Texas Tech University Health Sciences Center.

NCT01537029 is a Phase 4 study that has completed, run by Texas Tech University Health Sciences Center. The registered enrollment target is 15 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01537029, a Phase 4 study, has completed, sponsored by Texas Tech University Health Sciences Center.

COMPLETED
Registry status
Phase 4
Development phase
15 participants
Enrollment target

Study Summary

To determine the effect of weight on doxorubicin and cyclophosphamide plasma clearance in participants who are normal weight (body mass index \[BMI\] \< 25 kg/m2, overweight or class I obese (BMI 25-34.9 kg/m2), or class II-III obese (BMI ≥ 35 kg/m2). The hypothesis is that participants who weigh more will have higher doxorubicin and cyclophosphamide clearances than participants who weigh less. Restated, the area under the drug-concentration time profile, also known as the AUC, in participants will decrease as participant weight increases.

Primary Outcome

Cyclophosphamide analysis was not possible due to rapid drug degradation

Interventions

  • DRUG Cyclophosphamide
  • DRUG Doxorubicin

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2012-02
Est. Completion 2016-12
Phase Phase 4

What the finished NCT01537029 record still lists

NCT01537029 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower).

The record links to 0 conditions, and to 2 interventions - of which Cyclophosphamide is the first listed.

NCT01537029 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01537029 about?

NCT01537029 is a clinical study titled "Effect of Weight on the Population Pharmacokinetic Analysis of Doxorubicin and Cyclophosphamide". To determine the effect of weight on doxorubicin and cyclophosphamide plasma clearance in participants who are normal weight (body mass index \[BMI\] \< 25 kg/m2, overweight or class I obese (BMI 25-34.9 kg/m2), or class II-III obese (BMI ≥ 35 kg/m2). The hypothesis is that participants who weigh mo...

What is the current status of trial NCT01537029?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2012-02. Estimated completion is 2016-12.

What interventions are being tested in trial NCT01537029?

The interventions under investigation include: Cyclophosphamide (DRUG), Doxorubicin (DRUG).

Who is sponsoring clinical trial NCT01537029?

This trial is sponsored by Texas Tech University Health Sciences Center, which has 76 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01537029's enrollment target sits among peer trials

15 1880th of 2000 higher than 100 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01537029, the US trial registry maintained by the National Library of Medicine. NCT01537029 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.